Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
139.47
-1.50 (-1.06%)
Jan 28, 2026, 3:53 PM EST - Market open
Gilead Sciences Market Cap
Gilead Sciences has a market cap or net worth of $173.04 billion as of January 28, 2026. Its market cap has increased by 55.76% in one year.
Market Cap
173.04B
Enterprise Value
188.81B
1-Year Change
55.76%
Ranking
Category
Stock Price
$139.47
Market Cap Chart
Since December 1, 1998, Gilead Sciences's market cap has increased from $973.10M to $173.04B, an increase of 17,682.10%. That is a compound annual growth rate of 21.01%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 26, 2026 | 170.94B | 12.25% |
| Dec 31, 2025 | 152.28B | 32.28% |
| Dec 31, 2024 | 115.12B | 14.04% |
| Dec 29, 2023 | 100.94B | -6.25% |
| Dec 30, 2022 | 107.68B | 18.22% |
| Dec 31, 2021 | 91.08B | 24.72% |
| Dec 31, 2020 | 73.03B | -11.17% |
| Dec 31, 2019 | 82.21B | 1.60% |
| Dec 31, 2018 | 80.92B | -13.53% |
| Dec 29, 2017 | 93.58B | -0.81% |
| Dec 30, 2016 | 94.34B | -35.31% |
| Dec 31, 2015 | 145.83B | 2.55% |
| Dec 31, 2014 | 142.21B | 23.49% |
| Dec 31, 2013 | 115.15B | 106.93% |
| Dec 31, 2012 | 55.65B | 81.01% |
| Dec 30, 2011 | 30.74B | 4.49% |
| Dec 31, 2010 | 29.42B | -24.44% |
| Dec 31, 2009 | 38.94B | -16.37% |
| Dec 31, 2008 | 46.56B | 8.73% |
| Dec 31, 2007 | 42.82B | 43.43% |
| Dec 29, 2006 | 29.86B | 24.03% |
| Dec 30, 2005 | 24.07B | 58.92% |
| Dec 31, 2004 | 15.15B | 28.36% |
| Dec 31, 2003 | 11.80B | 76.49% |
| Dec 31, 2002 | 6.69B | 6.07% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 540.74B |
| AbbVie | 395.77B |
| AstraZeneca | 296.35B |
| Novartis AG | 291.50B |
| Novo Nordisk | 280.65B |
| Merck & Co. | 267.86B |
| Amgen | 189.18B |
| Pfizer | 150.67B |